Like Semaglutide, Tirzepatide is a once-weekly injectable medication used for long-term weight management and blood sugar regulation
Another remarkable takeaway from the meta-analysis is the high rate of GI-related AEs which comprised up to 50% of the total AEs for injectable tirzepatide
Incidence rates of 3-point MACE were 30.3 and 40.0 events per 1000 person-years for OW semaglutide and dulaglutide, respectively
Market Size & Forecast (2024-2031), By Product, USD Million Ozempic Trulicity Mounjaro Wegovy Rybelsus Saxenda Others Market Size & Forecast (2024-2031), By Route of Administration, USD Million Subcutaneous Oral Market Size & Forecast (2024-2031), By Application, USD Million Diabetes Obesity Others Market Size & Forecast (2024-2031), By End-user, USD Million Hospitals Specialty Clinics Home-care Settings Others Market Size & Forecast (2024-2031), By Region, USD Million North America US Canada Europe UK Germany France Italy Spain Rest of Europe Asia Pacific China India Japan Rest of Asia Pacific Latin America Middle East & Africa Key Strategic Questions Addressed What is the market size & forecast of the GLP-1 analogues market
The review process evaluates clinical effectiveness, adverse event data, manufacturing quality, dosing standards, labeling requirements, and post-marketing safety plans
